Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab

Autor: Andrea Ardizzoni, Valentina Ambrosini, Diletta Calabrò, Benedetta Fragomeno, Dalia Ricci, Paola Valeria Marchese, Francesca Fabbri, Stefano Fanti, Giulia Argalia, Filippo Gustavo Dall'Olio, Nicole Conci

Introduction: Immune checkpoint inhibitors (ICIs) have become the standard of care in the management of advanced non–small cell lung cancer (NSCLC). Nevertheless, only a small proportion of patients benefit from ICIs. The aim of the present study i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e89776ede928e0427b7119fa29d85b26
http://hdl.handle.net/11585/856399

Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy.

Autor: De Giglio A; Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Via Massarenti, 9, 40138, Bologna, Italy. andrea.degiglio2@unibo.it.; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy. andrea.degiglio2@unibo.it., Leonetti A; Medical Oncology Unit, University Hospital of Parma, Parma, Italy., Comito F; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy., Filippini DM; Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Via Massarenti, 9, 40138, Bologna, Italy.; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy., Mollica V; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy., Rihawi K; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy., Peroni M; Department of Medicine and Surgery, University of Parma, Parma, Italy., Mazzaschi G; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.; Department of Medicine and Surgery, University of Parma, Parma, Italy., Ricciotti I; Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Via Massarenti, 9, 40138, Bologna, Italy., Carosi F; Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Via Massarenti, 9, 40138, Bologna, Italy., Marchetti A; Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Via Massarenti, 9, 40138, Bologna, Italy., Rosellini M; Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Via Massarenti, 9, 40138, Bologna, Italy., Gagliano A; Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Via Massarenti, 9, 40138, Bologna, Italy., Favorito V; Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Via Massarenti, 9, 40138, Bologna, Italy., Nobili E; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy., Gelsomino F; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy., Melotti B; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy., Marchese PV; Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Via Massarenti, 9, 40138, Bologna, Italy., Sperandi F; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy., Di Federico A; Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Via Massarenti, 9, 40138, Bologna, Italy.; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy., Buti S; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.; Department of Medicine and Surgery, University of Parma, Parma, Italy., Perrone F; Medical Oncology Unit, University Hospital of Parma, Parma, Italy., Massari F; Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Via Massarenti, 9, 40138, Bologna, Italy.; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy., Pantaleo MA; Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Via Massarenti, 9, 40138, Bologna, Italy.; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy., Tiseo M; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.; Department of Medicine and Surgery, University of Parma, Parma, Italy., Ardizzoni A; Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Via Massarenti, 9, 40138, Bologna, Italy.; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.

Publikováno v: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Oct 03; Vol. 73 (12), pp. 246. Date of Electronic Publication: 2024 Oct 03.

Molecular Characterization of Advanced-Stage Melanomas in Clinical Practice Using a Laboratory-Developed Next-Generation Sequencing Panel.

Autor: Maloberti T; Solid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy., De Leo A; Solid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40138 Bologna, Italy., Coluccelli S; Solid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy., Sanza V; Solid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy., Gruppioni E; Solid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy., Altimari A; Solid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy., Comito F; Oncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy., Melotti B; Oncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy., Marchese PV; Oncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy., Dika E; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40138 Bologna, Italy.; Oncologic Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy., Venturi F; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40138 Bologna, Italy.; Oncologic Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy., Corti B; Pathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy., Ciccimarra G; Department of Pharmacy and Biotechnology, University of Bologna, 40138 Bologna, Italy., Ciceu CA; Department of Pharmacy and Biotechnology, University of Bologna, 40138 Bologna, Italy., Tallini G; Solid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40138 Bologna, Italy., de Biase D; Solid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.; Department of Pharmacy and Biotechnology, University of Bologna, 40138 Bologna, Italy.

Publikováno v: Diagnostics (Basel, Switzerland) [Diagnostics (Basel)] 2024 Apr 11; Vol. 14 (8). Date of Electronic Publication: 2024 Apr 11.

TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab.

Autor: Mollica V; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni - 15, Bologna, Italy; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy. Electronic address: veronica.mollica7@gmail.com., Tassinari E; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni - 15, Bologna, Italy; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy., Santoni M; Oncology Unit, Macerata Hospital, Via Santa Lucia 2, 62100 Macerata, Italy., Marchese PV; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni - 15, Bologna, Italy; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy., Giunchi F; Pathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy., Maloberti T; Solid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy., Tateo V; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni - 15, Bologna, Italy; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy., Ricci C; Pathology Unit, Maggiore Hospital-AUSL Bologna, Bologna, Italy., Rosellini M; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni - 15, Bologna, Italy; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy., Marchetti A; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni - 15, Bologna, Italy; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy., Fiorentino M; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy; Pathology Unit, Maggiore Hospital-AUSL Bologna, Bologna, Italy., Biase D; Pathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy; Department of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy., Massari F; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni - 15, Bologna, Italy.

Publikováno v: Pathology, research and practice [Pathol Res Pract] 2024 Jan; Vol. 253, pp. 155008. Date of Electronic Publication: 2023 Dec 08.

Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers.

Autor: Marchese PV; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Via Albertoni - 15 40138, Bologna, Italy., Mollica V; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Via Albertoni - 15 40138, Bologna, Italy.; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy., Tassinari E; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Via Albertoni - 15 40138, Bologna, Italy., De Biase D; Department of Pharmacy and Biotechnology (Fabit), University of Bologna, 40138 Bologna, Italy.; Solid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy., Giunchi F; Pathology Unit, IRCCS Policlinico Sant'Orsola-Malpighi, University of Bologna, Bologna, Italy., Marchetti A; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Via Albertoni - 15 40138, Bologna, Italy., Rosellini M; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Via Albertoni - 15 40138, Bologna, Italy., Fiorentino M; Pathology Unit, Maggiore Hospital, AUSL Bologna, Bologna, Italy., Massari F; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Via Albertoni - 15 40138, Bologna, Italy.; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.

Publikováno v: Expert review of molecular diagnostics [Expert Rev Mol Diagn] 2022 Nov; Vol. 22 (11), pp. 997-1008. Date of Electronic Publication: 2022 Dec 12.